camrelizumab + apatinib + gemcitabine + oxaliplatin + tegafur

This is a multi-agent combination regimen consisting of five drugs with distinct mechanisms targeting cancer through immunotherapy, antiangiogenesis, and cytotoxic chemotherapy. **Camrelizumab** is a humanized monoclonal antibody that inhibits the programmed death 1 (PD‑1) receptor on T cells, thereby enhancing antitumor immune responses. **Apatinib** is an oral small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting tumor angiogenesis. **Gemcitabine** is a nucleoside analog that interferes with DNA synthesis and induces apoptosis in rapidly dividing cells. **Oxaliplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and cell death. **Tegafur**, often used as part of the oral fluoropyrimidine S‑1 or UFT formulations, is a prodrug of 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. This combination leverages immune checkpoint blockade with antiangiogenic therapy to modulate the tumor microenvironment while simultaneously delivering cytotoxic agents to maximize antitumor efficacy. It has been explored primarily for advanced solid tumors such as hepatocellular carcinoma and gastrointestinal cancers[1][2][3][7].

Other names

camrelizumab + apatinib + gemcitabine + oxaliplatin + tegafur